Field Trip Health & Wellness Ltd.
FTHWF
Other OTC0.04
USD
- -
- -
CIK
0001941771
ISIN
CA31656Q1046
Return %
Stock
S&P500
1Y
-81.08
19.01
3Y
-81.08
65.48
5Y
-81.08
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ronan Levy
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 30 Duncan Street Toronto ON Canada M5V 2C3
- IPO Date
- Aug 18, 2022
- CIK
- 0001941771
- Website
- fieldtriphealth.com
- Similar Companies
- Business
- Field Trip Health & Wellness Ltd. operates in the psychedelic therapy and mental health care sector, specializing in ketamine-assisted psychotherapy and related mental health services. The company's core offerings include ketamine-assisted therapy programs administered through a network of clinics, incorporating musculoskeletal ketamine injections, ketamine lozenges, and psychotherapy services designed to treat conditions such as anxiety, depression, PTSD, and other mental health disorders. Additionally, Field Trip provides advanced treatments such as the Stellate Ganglion Block (SGB) protocol called Dual Sympathetic Reset (DSR), which is aimed at alleviating symptoms of anxiety, depression, and PTSD. The company also delivers digital mental health support through its Field Trip app, which facilitates guided meditations, music, and mindfulness tools to enhance patient experiences. Founded in 2019 and headquartered in Toronto, Canada, Field Trip operates primarily in North America with over 20 clinic locations across the United States. The company emerged from a split in May 2022, separating into Field Trip Health and Wellness, focused on medical care and therapy services, and a separate entity, Reunion Neuroscience, dedicated to drug development research, particularly around psychedelic compounds like FT-104. In recent developments, Field Trip Health & Wellness faced financial difficulties leading to closure of several clinics and staff layoffs in early 2023, followed by protection from creditors under Canadian insolvency proceedings. The majority of its U.S. clinical assets were acquired by Stella, a behavioral health provider specializing in PTSD treatment, which plans to expand the acquired clinic operations and integrate Field Trip's research, technology, and outcome data to broaden its treatment offerings. Field Trip also secured approximately CAD 20 million in funding from investors including Reunion Neuroscience and Oasis Management Company, supporting ongoing operations and clinical trials. The company's strategic focus remains on delivering advanced psychedelic therapies and expanding its footprint in the mental health services industry. Field Trip's business model targets mental health patients seeking innovative psychedelic-assisted treatments and integrates both in-person clinical programs and digital therapeutic tools. Its offerings include ketamine as a legally approved psychedelic for mental health applications, ancillary psychotherapy, and emerging treatments leveraging advanced neuromodulation techniques. The company's operations and recent restructuring highlight a strategic pivot towards sustainability through partnerships and asset sales while maintaining innovation in mental health treatment modalities.
Field Trip Health & Wellness Ltd. to Release Fiscal 2023 Third Quarter Financial Results on Tuesday, February 28, 2023
Psychedelic Sunday: Ketamine Assisted Therapy